Cyteir Therapeutics, Inc.

Biopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte

Since it has become difficult for many biopharmaceutical companies to raise money during the past year and a half, several firms have been forced to cut costs to make remaining cash balances last long

Raising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr

Lightstone Ventures has closed its third fund – its largest to date – with $375m to fund early stage biopharmaceutical and medical technology companies after several successful exits via initial publi